NCT04330716 (GeneBOPP) is a NA clinical trial of Standard Genetic Counseling in Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT04330716?

NCT04330716 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT04330716?

Interventions in NCT04330716: Standard Genetic Counseling, Educational Video.

What condition does NCT04330716 study?

NCT04330716 studies Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Metastatic Prostate Cancer.

Is NCT04330716 still recruiting?

NCT04330716 is currently completed. Last updated 19 January 2024.

Last reviewed 2024-01-19 · How we verify

NCT04330716: GeneBOPP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

Completed NA Last updated 19 January 2024

What this trial tests

NA trial testing Standard Genetic Counseling in Breast Cancer in 269 participants. Completed in 31 December 2023.

Timeline

1 December 2020

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	269
Start date	1 December 2020
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	6 locations across United States

Drugs / interventions tested

Standard Genetic Counseling
Educational Video

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Ovarian Cancer — all drugs for Ovarian Cancer →
Pancreatic Cancer — all drugs for Pancreatic Cancer →
Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Breast Cancer or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.
Rana HQ, Stopfer JE, Weitz M, Kipnis L, et al · · 2023 · cited 14× · PMID 37733980 · DOI 10.1200/op.23.00007
Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized Study.
Schneider KA, Massingham L, Weitz M, Phornphutkul C, et al · · 2025 · cited 1× · PMID 40209136 · DOI 10.1200/op-24-00809

Verify or expand the search:

Other trials of Standard Genetic Counseling

Trials testing the same drug.

NCT04725565 — Genetics Adviser: Evaluating a Digital Decision Support Tool for Genetic Results · NA · completed
NCT04245176 — Genetic Testing for All Breast Cancer Patients (GET FACTS) · NA · active not recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04330716 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 19 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04330716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing